Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes
Journal for ImmunoTherapy of Cancer · 2024-06 · 12 (6) · e008667
DOI: 10.1136/jitc-2023-008667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 10.06.2024. Verfasst von Junha Cha und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Single-Cell Analysis, Immunotherapy, Papillomavirus Infections. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Drug Development Fund, Brain Korea 21 (BK21) FOUR Program, Ministry of Science and ICT.
Abstract (Originalsprache)
Background
Oropharyngeal squamous cell carcinoma (OPSCC) induced by human papillomavirus (HPV-positive) is associated with better clinical outcomes than HPV-negative OPSCC. However, the clinical benefits of immunotherapy in patients with HPV-positive OPSCC remain unclear.
Methods
To identify the cellular and molecular factors that limited the benefits associated with HPV in OPSCC immunotherapy, we performed single-cell RNA (n=20) and T-cell receptor sequencing (n=10) analyses of tonsil or base of tongue tumor biopsies prior to immunotherapy. Primary findings from our single-cell analysis were confirmed through immunofluorescence experiments, and secondary validation analysis were performed via publicly available transcriptomics data sets.
Results
We found significantly higher transcriptional diversity of malignant cells among non-responders to immunotherapy, regardless of HPV infection status. We also observed a significantly larger proportion of CD4 + follicular helper T cells (Tfh) in HPV-positive tumors, potentially due to enhanced Tfh differentiation. Most importantly, CD8 + resident memory T cells (Trm) with elevated KLRB1 (encoding CD161) expression showed an association with dampened antitumor activity in patients with HPV-positive OPSCC, which may explain their heterogeneous clinical outcomes. Notably, all HPV-positive patients, whose Trm presented elevated KLRB1 levels, showed low expression of CLEC2D (encoding the CD161 ligand) in B cells, which may reduce tertiary lymphoid structure activity. Immunofluorescence of HPV-positive tumors treated with immune checkpoint blockade showed an inverse correlation between the density of CD161 + Trm and changes in tumor size.
Conclusions
We found that CD161 + Trm counteracts clinical benefits associated with HPV in OPSCC immunotherapy. This suggests that targeted inhibition of CD161 in Trm could enhance the efficacy of immunotherapy in HPV-positive oropharyngeal cancers. Trial registration number NCT03737968 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
- Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
- The Gene Lay Institute of Immunology and Inflammation, Brigham and Women's Hospital, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
- Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Min Hee Hong, Sang-Jun Ha, Hye Ryun Kim, Insuk Lee
Förderung
- Korea Drug Development Fund
- Brain Korea 21 (BK21) FOUR Program
- Ministry of Science and ICT
- Yonsei Fellow Program
- Korean Foundation for Cancer Research
Zitieren
APA
Cha, J., Kim, D. H., Kim, G., Cho, J. W., Sung, E., Baek, S., Hong, M. H., Kim, C. G., Sim, N. S., Hong, H. J., Lee, J. E., Hemberg, M., Park, S., Yoon, S. O., Ha, S. J., Koh, Y. W., Kim, H. R., & Lee, I. (2024). Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes. Journal for ImmunoTherapy of Cancer, 12(6), e008667. https://doi.org/10.1136/jitc-2023-008667
Vancouver
Cha J, Kim DH, Kim G, Cho JW, Sung E, Baek S, et al. Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes. Journal for ImmunoTherapy of Cancer. 2024;12(6):e008667. doi:10.1136/jitc-2023-008667
BibTeX
@article{Cha2024,
author = {Cha, Junha and Kim, Da Hee and Kim, Gamin and Cho, Jae-Won and Sung, Euijeong and Baek, Seungbyn and Hong, Min Hee and Kim, Chang Gon and Sim, Nam Suk and Hong, Hyun Jun and Lee, Jung Eun and Hemberg, Martin and Park, Seyeon and Yoon, Sun Ock and Ha, Sang-Jun and Koh, Yoon Woo and Kim, Hye Ryun and Lee, Insuk},
title = {Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {6},
pages = {e008667},
doi = {10.1136/jitc-2023-008667}
}
EUVIMED